Effects of alendronate and risedronate therapy on hepatic antioxidant enzyme activity and lipid peroxidation in ovariectomized rats
To evaluate the effects of alendronate (ALN) and risedronate (RIS), which are agents for preventing and treating postmenopausal osteoporosis, on hepatic antioxidant enzyme activity and lipid peroxidation in ovariectomized rats. Materials and methods: Thirty-two female rats were randomly assigned to 4 separate groups. All of the groups, except the control group, were ovariectomized. Included in the 4 groups were a control group (C), an ovariectomized group (OVX), an ovariectomized group treated with alendronate (OVX-ALN), and an ovariectomized group treated with risedronate (OVX-RIS). Ten weeks after an ovariectomy, the OVX-ALN rats were administered 1.75 mg/kg of their body weight with alendronate sodium; and the OVX-RIS rats were administered 0.5 mg/kg of their body weight with risedronate sodium. Both doses were administered by gavage twice per week for 12 weeks. At the end of the treatment period, the liver enzyme activity levels of superoxide dismutase (SOD) and catalase (CAT) and malondialdehyde (MDA) levels were measured. Results: There were significantly elevated levels of MDA observed in the OVX and OVX-ALN groups, whereas the MDA concentration significantly decreased in the OVX-RIS group when compared to the control animals. The SOD activity was significantly higher in the OVX and OVX-ALN groups, but there was no statistically significant difference in the SOD activity in the OVX-RIS group when compared with that of the control group. Moreover, CAT activity declined significantly in the OVX group and was elevated in the OVX-ALN group, according to the control group. No significant change in CAT activity was observed in the OVX-RIS group. Conclusion: Alendronate increases the effect of ovariectomy on lipid peroxidation, and induces oxidative stress; however, risedronate prevents oxidative stress caused by an ovariectomy.
Effects of alendronate and risedronate therapy on hepatic antioxidant enzyme activity and lipid peroxidation in ovariectomized rats
To evaluate the effects of alendronate (ALN) and risedronate (RIS), which are agents for preventing and treating postmenopausal osteoporosis, on hepatic antioxidant enzyme activity and lipid peroxidation in ovariectomized rats. Materials and methods: Thirty-two female rats were randomly assigned to 4 separate groups. All of the groups, except the control group, were ovariectomized. Included in the 4 groups were a control group (C), an ovariectomized group (OVX), an ovariectomized group treated with alendronate (OVX-ALN), and an ovariectomized group treated with risedronate (OVX-RIS). Ten weeks after an ovariectomy, the OVX-ALN rats were administered 1.75 mg/kg of their body weight with alendronate sodium; and the OVX-RIS rats were administered 0.5 mg/kg of their body weight with risedronate sodium. Both doses were administered by gavage twice per week for 12 weeks. At the end of the treatment period, the liver enzyme activity levels of superoxide dismutase (SOD) and catalase (CAT) and malondialdehyde (MDA) levels were measured. Results: There were significantly elevated levels of MDA observed in the OVX and OVX-ALN groups, whereas the MDA concentration significantly decreased in the OVX-RIS group when compared to the control animals. The SOD activity was significantly higher in the OVX and OVX-ALN groups, but there was no statistically significant difference in the SOD activity in the OVX-RIS group when compared with that of the control group. Moreover, CAT activity declined significantly in the OVX group and was elevated in the OVX-ALN group, according to the control group. No significant change in CAT activity was observed in the OVX-RIS group. Conclusion: Alendronate increases the effect of ovariectomy on lipid peroxidation, and induces oxidative stress; however, risedronate prevents oxidative stress caused by an ovariectomy.
